BI 764532
Boehringer Ingelheim
['sclc']
7: as for tumor response, in patients with sclc or nec who received target dose of bi 764532, orr was 33% and 22% across all regimens, respectively. this demonstrates promising early efficacy. #asco23 #cancerresearch 
🫁Pneumo-Onco🩺 Chef de Pôle de Méd à Orientation Onco 🏥 @CHToulonLaSeyne 🔬Conseil Scientifique @IFCTLung / Pdte du 3C VarOuest 👉🏼#HopitalPublic #LungCancer